NCT05709821 — "IMM60 and Pembrolizumab in Melanoma and NSCLC" trial site landscape

Public-registry site landscape for NCT05709821, “IMM60 and Pembrolizumab in Melanoma and NSCLC”, a Non-small Cell Lung Cancer study sponsored by iOx Therapeutics. All data below is from public sources; Eichor is not affiliated with the sponsor.

Trial	NCT05709821 (registry record)
Study title	IMM60 and Pembrolizumab in Melanoma and NSCLC
Official title	IMPORT-201: A Phase 1 First-in-Human Dose Finding/Randomized Phase 2 Study of IMM60 and Pembrolizumab for Advanced Melanoma and Metastatic NSCLC
Sponsor	iOx Therapeutics
Condition(s)	Non-small Cell Lung Cancer; Melanoma
Phase	PHASE1 / PHASE2
Listed sites	14
Site countries	United States, Spain, United Kingdom

Patient-friendly overview of this study: eichor.com/study/NCT05709821.

Free site-risk snapshot for this trial

Eichor generates a preliminary site-risk snapshot for NCT05709821 — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →

Related trials

Other Non-small Cell Lung Cancer trials

← Eichor home · All tracked trials · Non-small Cell Lung Cancer studies · Weekly briefs

Planning or rescuing a trial? Eichor generates evidence-linked site-risk reports from public data in minutes. Get a free preliminary snapshot →